FindTrial
Sign In

Understanding the Causes and Treatment Results of Eye Vein Blockage

Analysis of risk factors and outcome of Intravitreal anti-VEGF in retinal vein occlusion - NIL

Status
Active, not recruiting
Phases
Unknown
Study type
Observational
Source
CTRI
Registry ID
CTRI/2025/10/095834
Enrollment
40
Registered
2025-10-09
Start date
Unknown
Completion date
Unknown
Last updated
2025-10-13

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Health Condition 1: H348- Other retinal vascular occlusions

Interventions

Intervention1: Nil: Nil Intervention2: Nil: Nil Intervention3: NIL: NIL

Sponsors

SUTHIKSHA V
Lead Sponsor

Eligibility

Inclusion criteria

Inclusion criteria: Treatment naive cases of RVO Presence of clinically significant macular oedema secondary to RVO confirmed by OCT BCVA of 6 by 12 to 6 by 60 in the study eye CMT or CFT above 300 micrometer

Exclusion criteria

Exclusion criteria: Previous treatment for RVO in the study eye Retinal diseases other than RVO Significant media opacities Recent history of thromboembolic events

Design outcomes

Primary

MeasureTime frame
Role of biochemical markers in patients newly diagnosed with Retinal Vein Occlusion (RVO)Timepoint: Baseline first visit, Post injection 1week, 1month, 3months—

Secondary

MeasureTime frame
Therapeutic response in relation to pre-treatment biomarker influenceTimepoint: Baseline first visit, Post injection 1week,1month, 3months—

Countries

India

Contacts

Public ContactSUTHIKSHA V

Sankara Eye Hospital Coimbatore

geetha@sankaraeye.com9442016032

Outcome results

None listed

Source: CTRI (via WHO ICTRP) · Data processed: Feb 4, 2026